Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 3/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP4 | P49662 | 1/20 | 0.42 |
| ▸ | CASP5 | P51878 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.40 |
| ▸ | LIPC | P11150 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL519004 | 0.76 | PRKAA2 (1.00) | PRKAA2ADRB2 | |
| SCHEMBL12239157 | 0.71 | PRKAA2 (0.64) | PRKAA2ADRB2CASP1CASP4CASP5 | |
| SCHEMBL1006219 | 0.70 | PRKAA2 (0.62) | PRKAA2ADRB2PPARDPPARAHRH3 | |
| SCHEMBL12099440 | 0.69 | FFAR1 (0.39) | PRKAA2 | |
| SCHEMBL29716554 | 0.69 | ADRB2 (0.64) | PRKAA2ADRB2HRH3 | |
| SCHEMBL10608877 | 0.69 | HRH3 (0.64) | ADRB2KCNH2HRH3 | |
| SCHEMBL27644534 | 0.68 | PDE2A (0.52) | — | |
| Hydrochloric Acid SCHEMBL31586806 | 0.68 | ADRB2 (0.63) | PRKAA2ADRB2HRH3 | |
| SCHEMBL12239156 | 0.68 | PRKAA2 (0.59) | PRKAA2ADRB2KCNH2MCHR1HRH3 | |
| Hydrochloric Acid SCHEMBL10610506 | 0.68 | SMN1; SMN2 (0.65) | ADRB2KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266856-B2 | AMPK—activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140315884-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315884-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | PRKAA2 7/4885ADRB2 1357/4885RPS6KB1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.